Financial Disclosures: Drs Okin, Devereux,
and Nieminen have received grant support, honoraria for lectures about the
LIFE study, and funding for consulting and lecturing from Merck, respectively;
Dr Snapinn was a Merck employee.
Author Contributions: Dr Okin had full access
to all of the data in this study and takes responsibility for the integrity
of the data and the accuracy of the data analyses.
Study concept and design: Okin, Devereux, Julius,
Nieminen, Snapinn, Aurup, Edelman, Wedel, Dahlöf.
Acquisition of data: Jern, Kjeldsen, Julius,
Nieminen, Snapinn, Harris, Aurup, Edelman, Wedel, Dahlöf.
Analysis and interpretation of data: Okin,
Julius, Snapinn, Harris, Aurup, Edelman, Wedel, Lindholm, Dahlöf.
Drafting of the manuscript: Okin, Julius, Aurup,
Critical revision of the manuscript for important
intellectual content: Okin, Devereux, Jern, Kjeldsen, Julius, Nieminen,
Snapinn, Harris, Aurup, Edelman, Wedel, Lindholm, Dahlöf.
Statistical analysis: Okin, Julius, Snapinn,
Obtained funding: Devereux, Kjeldsen, Julius,
Aurup, Edelman, Wedel, Dahlöf.
Administrative, technical, or material support:
Devereux, Julius, Nieminen, Aurup, Edelman, Wedel.
Study supervision: Julius, Edelman, Wedel,
Funding/Support: The LIFE study was supported
in part by grant COZ-368 from Merck & Co Inc.
Role of the Sponsor: All study data reside
in the Merck & Co Inc database. Merck provided the study authors with
free access to all of the data; the authors were free to interpret data and
write the paper and the outcome was independently validated by the steering
committee statistician. The sponsor agreed to support the performance of the
study, at which time it was also agreed that the findings would be published
by the investigators regardless of the results. The decision to publish the
paper, the choice of analyses to include, and the drafting of the manuscript
were wholly controlled by Dr Okin and coauthor members of the LIFE Electrocardiographic